3
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Acromegaly caused by a GHRH-producing pancreatic neuroendocrine tumor: a rare manifestation of MEN1 syndrome

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Summary

          Multiple endocrine neoplasia type 1 NM_001370259.2(MEN1):c.466G>C(p.Gly156Arg) is characterized by tumors of various endocrine organs. We report on a rare, growth hormone-releasing hormone (GHRH)-releasing pancreatic tumor in a MEN1 patient with a long-term follow-up after surgery. A 22-year-old male with MEN1 syndrome, primary hyperparathyroidism and an acromegalic habitus was observed to have a pancreatic tumor on abdominal CT scanning, growth hormone (GH) and insulin-like growth factor 1 (IGF1) were elevated and plasma GHRH was exceptionally high. GHRH and GH were measured before the treatment and were followed during the study. During octreotide treatment, IGF1 normalized and the GH curve was near normal. After surgical treatment of primary hyperparathyroidism, a pancreatic tail tumor was enucleated. The tumor cells were positive for GHRH antibody staining. After the operation, acromegaly was cured as judged by laboratory tests. No reactivation of acromegaly has been seen during a 20-year follow-up. In conclusion, an ectopic GHRH-producing, pancreatic endocrine neoplasia may represent a rare manifestation of MEN1 syndrome.

          Learning points
          • Clinical suspicion is in a key position in detecting acromegaly.

          • Remember genetic disorders with young individuals having primary hyperparathyroidism.

          • Consider multiple endocrine neoplasia type 1 syndrome when a person has several endocrine neoplasia.

          • Acromegaly may be of ectopic origin with patients showing no abnormalities in radiological imaging of the pituitary gland.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: found

          ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

            • Record: found
            • Abstract: found
            • Article: not found

            Multiple Endocrine Neoplasia

            Early diagnosis of multiple endocrine neoplasia (MEN) syndromes is critical for optimal clinical outcomes; before the MEN syndromes can be diagnosed, they must be suspected. Genetic testing for germline alterations in both the MEN type 1 (MEN1) gene and RET proto-oncogene is crucial to identifying those at risk in affected kindreds and directing timely surveillance and surgical therapy to those at greatest risk of potentially life-threatening neoplasia. Pancreatic, thymic, and bronchial neuroendocrine tumors are the leading cause of death in patients with MEN1 and should be aggressively considered by at least biannual computed tomography imaging.
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases.

              Ectopic GHRH secretion is a rare cause of acromegaly, and case reports are mainly isolated. From the registry of the sole laboratory performing plasma GHRH assays in France, we identified cases of ectopic GHRH secretion presenting with acromegaly between 1983 and 2008. Twenty-one patients aged 14-77 yr were identified from 12 French hospitals. Median GHRH was 548 (270-9779) ng/liter. Outcome measures included description of tumor features and outcome and the relation between plasma GHRH values and tumor site, size, and spread. The primary neuroendocrine tumor was identified for 20 of 21 patients (12 pancreatic, seven bronchial, one appendicular). Tumors were large (10-80 mm), identified on computed tomography scan in 18 cases and by endoscopic ultrasound and somatostatin receptor scintigraphy in two. Somatostatin receptor scintigraphy had a similar sensitivity to computed tomography scan (81 vs. 86%). Tumors were all well differentiated; 47.6% had metastasized at the time of diagnosis of acromegaly. After a median follow-up of 5 yr, 85% of patients were alive. Ninety-one percent of patients whose tumor was completely removed were considered in remission, and most had normalized plasma GHRH. The remaining patients were treated with somatostatin analogs: IGF-I normalized except for one patient who required pegvisomant, but GHRH levels remained elevated. No correlations were found between GHRH levels and tumor site or size or the existence of metastases. Identification of increased plasma GHRH during follow-up was an accurate indicator of recurrence. The prognosis of endocrine tumors responsible for GHRH secretion appears relatively good. Plasma GHRH assay is an accurate tool for diagnosis and follow-up.

                Author and article information

                Journal
                Endocrinol Diabetes Metab Case Rep
                Endocrinol Diabetes Metab Case Rep
                EDM
                Endocrinology, Diabetes & Metabolism Case Reports
                Bioscientifica Ltd (Bristol )
                2052-0573
                27 January 2022
                2022
                : 2022
                : 21-0079
                Affiliations
                [1 ]Department of Internal Medicine , University of Oulu and Oulu University Hospital, Oulu, Finland
                [2 ]Department of Pathology , University of Oulu, Oulu, Finland
                [3 ]Institute of Biomedicine , University of Oulu, Oulu, Finland
                [4 ]Department of Otorhinolaryngology , University of Oulu and Oulu University Hospital, Oulu, Finland
                [5 ]Department of Internal Medicine , Central Finland Central Hospital, Jyväskylä, Finland
                Author notes
                Correspondence should be addressed to M Koivikko; Email: minna.l.koivikko@ 123456ppshp.fi
                Author information
                http://orcid.org/0000-0001-7227-966X
                Article
                EDM210079
                10.1530/EDM-21-0079
                8897594
                35199646
                0c733a37-d97b-4dfd-bc4c-3bb1045d96a9
                © The authors

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License..

                History
                : 10 December 2021
                : 27 January 2022
                Categories
                Adult
                Male
                White
                Finland
                Pancreas
                Neuroendocrinology
                Tumours and Neoplasia
                Gastroenterology
                General Practice
                Genetics
                Insight into Disease Pathogenesis or Mechanism of Therapy
                Insight into Disease Pathogenesis or Mechanism of Therapy

                adult,male,white,finland,pancreas,neuroendocrinology,tumours and neoplasia,gastroenterology,general practice,genetics,insight into disease pathogenesis or mechanism of therapy,february,2022

                Comments

                Comment on this article

                Related Documents Log